Minimed Group/$MMED
1D1W1MYTD1Y5YMAX
Capital at risk
About Minimed Group
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.
- Ticker
- $MMED
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Northridge, United States
- Website
- www.minimed.com
Minimed Group Metrics
BasicAdvanced
$6.3B
-
-$1.19
-
-
Price and volume
Market cap
$6.3B
52-week high
$24.43
52-week low
$10.65
Average daily volume
1.6M
Financial strength
Current ratio
1.812
Quick ratio
1.265
Long term debt to equity
1.381
Total debt to equity
1.63
Profitability
EBITDA (TTM)
280.25
Gross margin (TTM)
56.67%
Net profit margin (TTM)
-9.75%
Operating margin (TTM)
3.76%
Effective tax rate (TTM)
-75.00%
Management effectiveness
Return on equity (TTM)
-8.66%
Valuation
Price to revenue (TTM)
1.836
Price to book
1.74
Price to tangible book (TTM)
5.05
Price to free cash flow (TTM)
-18.722
Free cash flow yield (TTM)
-5.34%
Free cash flow per share (TTM)
-1.199
Growth
Revenue change (TTM)
15.65%
Earnings per share change (TTM)
39.32%
What the Analysts think about Minimed Group
Analyst ratings (Buy, Hold, Sell) for Minimed Group stock.
Analyst projections of the future price of Minimed Group stock.
Bulls say / Bears say
MiniMed Group returned to growth in recent quarters driven by strong uptake of its MiniMed 780G automated insulin delivery system and sensor enhancements, reversing previous declines and demonstrating robust demand (Reuters).
Medtronic secured CE Mark for the MiniMed 780G system with the Abbott-made Instinct sensor in February 2026, paving the way for a summer launch in Europe and access to over 4.5 million Abbott sensor users (Reuters).
Medtronic Diabetes expanded U.S. pharmacy formulary access for the MiniMed 780G insulin pump through agreements with major PBMs and GPOs, broadening coverage beyond DME channels and simplifying access for eligible patients (PR Newswire).
Shares opened 4.8% below their $20 IPO price in the Nasdaq debut, valuing MiniMed at approximately $5.35 billion and signaling tepid investor demand (Reuters).
Medtronic plc retains approximately 90.03% of MiniMed’s outstanding shares post-IPO, limiting public free float to under 10% and constraining stock liquidity and minority shareholder influence (SEC).
After closing its IPO at $20, MMED shares slid to $18.02, down 7.55% over the week and trading near a 52-week low of $18.25, reflecting ongoing weak secondary market performance (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Minimed Group Financial Performance
Revenues and expenses
Minimed Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Minimed Group News
AllArticlesVideos
Funds containing Minimed Group
Fund name | Fund size | $MMED weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.